EGFR-TKI AFTER DISEASE PROGRESSION WITH CENTRAL NERVOUS SYSTEM METASTASIS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS

被引：0
|
作者：
Kasahara, Kazuo [1 ]
Sone, Takashi [1 ]
Shibata, Kazuhiko [2 ]
Shirasaki, Hiroki [3 ]
Kita, Toshiyuki [4 ]
Sakai, Asao [5 ]
Nishikawa, Shingo [6 ]
Yoneda, Taro [1 ]
Kimura, Hideharu [1 ]
机构：
[1] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[2] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[3] Fukui Ken Saiseika Hosp, Fukui, Japan
[4] Nho Kanazawa Med Ctr, Kanazawa, Ishikawa, Japan
[5] Keijyu Med Ctr, Nanao, Japan
[6] Kanazawa Social Insurance Hosp, Kanazawa, Ishikawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR tyrosine kinase inhibitor; EGFR mutation; Beyond Progressive Disease;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-045
引用
收藏
页码：S1210 / S1210
页数：1
相关论文
共 50 条
  • [1] EGFR-TKI after disease progression with central nervous system metastasis in advanced non-small cell lung cancer with EGFR mutations.
    Sone, Takashi
    Kasahara, Kazuo
    Kurokawa, Koji
    Sakai, Asao
    Kita, Toshiyuki
    Nishikawa, Shingo
    Watanabe, Kazuyoshi
    Shirasaki, Hiroki
    Yoneda, Taro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Kogure, Yoshihito
    Saka, Hideo
    Oki, Masahide
    Saito, Toshiki I.
    Ahmed, Shimaa Nour Moursi
    Kitagawa, Chiyoe
    Imaizumi, Kazuyoshi
    PLOS ONE, 2015, 10 (08):
  • [3] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Analysis of the EGFR mutations in non-small cell lung cancer patients after EGFR-TKI treatment.
    Yamaguchi, H.
    Ikeda, T.
    Tomonaga, N.
    Nakano, H.
    Kitazaki, T.
    Doi, S.
    Nakatomi, K.
    Iida, T.
    Nakamura, Y.
    Kohno, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [6] Progression of central nervous system metastases in advanced non-small cell lung cancer patients effectively treated with first-generation EGFR-TKI
    Yu, M.
    Zhao, Q.
    Li, Y.
    Zhang, S.
    Zhou, X.
    Wang, J.
    Wang, Y.
    Lu, Y.
    Liu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S109 - S110
  • [7] The Abundance of EGFR Mutations Could Be More Better Predictor for EGFR-TKI Therapy in Advanced Non-Small Cell Lung Cancer
    Li, Xuefei
    Su, Chunxia
    Zhao, Chao
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S310 - S310
  • [8] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, (04) : 270 - 276
  • [9] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [10] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, 11 (04) : 270 - 276
12345